¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)
Global Breast Cancer Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
À¯¹æ¾Ï Áø´Ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 52¾ï 2,000¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â ¾à 104¾ï 7,000¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³â CAGR·Î 8.05%ÀÇ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.
À¯¹æ¾Ï Áø´Ü¿¡´Â À¯¹æ¾ÏÀ» ´Ü°èº°·Î ½Äº°ÇÏ°í Æò°¡Çϱâ À§ÇÑ ´Ù¾çÇÑ ±â¼ú°ú ÅøÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ºÐ¾ß¿¡¼´Â À¯¹æÃÔ¿µ, ÃÊÀ½ÆÄ, MRI µî ¿µ»óÁø´Ü¹ý, »ý°Ë¹ý, ºÐÀÚ°Ë»ç µîÀ» °áÇÕÇÏ¿© Á¤È®ÇÑ Áø´Ü°ú º´±â ºÐ·ù¸¦ ¼öÇàÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü ¹æ¹ýÀº ¹ß°ß¿¡ ÀÏÀÍÀ» ´ã´çÇϰí Ä¡·áÀÇ Àü¸Á°ú È¿°ú¸¦ Å©°Ô Çâ»ó½Ãŵ´Ï´Ù. ÃֽŠÁø´Ü Àü·«Àº Á¾Á¾ ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó½Ã۱â À§ÇØ ±â¼úÀ» ÅëÇÕÇÏ¿© ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ÀûÀýÇÑ ´Ü°è¿¡¼ Á¾¾çÀ» ¹ß°ß ÇÒ ¼ö ÀÖµµ·ÏÇÕ´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÃÖ±Ù ¹ßÀü¿¡´Â Á¤È®ÇÑ 3Â÷¿ø ¿µ»ó Áø´ÜÀ» À§ÇÑ À¯¹æ Åä¸ð»ðÀÔ¼ú°ú ºñħ½ÀÀû ¾Ï °ËÃâÀ» À§ÇØ ¼øÈ¯ Á¾¾ç DNA¸¦ °Ë»çÇÏ´Â ¾×ü»ý°ËÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ÅëÇÕÀû Á¢±Ù ¹æ½ÄÀº °³Àκ° ¸ÂÃã Ä¡·á °èȹÀ» º¸ÀåÇϰí, ±Ã±ØÀûÀ¸·Î ȯÀÚ °á°ú¿Í ¸ÂÃãÇü ÀÇ·áÀÇ Áøº¸¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ
À¯¹æ¾Ï Áø´Ü ½ÃÀåÀº À¯¹æ¾Ï ¹ßº´·ü Áõ°¡, Áø´Ü ±â¼ú ¹ßÀü, Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎ´ã Áõ°¡´Â Áø´Ü Åø ¹× ¼ºñ½º °ÈÀÇ Çʿ伺À» °Á¶Çϰí ÀÖÀ¸¸ç, MRI, µðÁöÅÐ À¯¹æ Á¶¿µ¼ú, Çõ½ÅÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿¿Í °°Àº ±â¼ú ¹ßÀüÀº Áø´ÜÇÐÀ» º¯È½Ã۰í Á¶±â ¹ß°ßÀ» °³¼±Çϸç Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¿µ»ó Áø´Ü¿¡¼ AIÀÇ °³¹ßÀº À¯¹æ¾Ï °ËÃâÀÇ Á¤È®µµ¸¦ Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Áö¸à½º ÇïÆ¼´Ï¾î½º(Siemens Healthineers)¿Í GEÇコÄɾî(GE Healthcare)¿Í °°Àº ÁÖ¿ä ±â¾÷Àº ¹æ»ç¼±°ú Àü¹®Àǰ¡ ´õ ³ôÀº Á¤È®µµ¿Í È¿À²¼ºÀ¸·Î ÀÌ»ó ¡Èĸ¦ ½Äº°ÇÒ ¼ö ÀÖµµ·Ï AI ¾Ë°í¸®ÁòÀ» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ±âȸ´Â ȯÀÚ °³°³ÀÎÀÇ ¸ÂÃã Ä¡·á¸¦ À§ÇÑ °í±Þ Áø´Ü ÅøÀ» ÇÊ¿ä·Î ÇÏ´Â ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤Åà Ȯ´ë¿¡ µû¶ó ´õ¿í ÃËÁøµÉ °ÍÀÔ´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì ±â¼ú°ú ¾×ü»ý°ËÀÇ µµÀÔÀº ºñħ½ÀÀû ¸ð´ÏÅ͸µ°ú Á¤¹ÐÁø´ÜÀÇ »õ·Î¿î ±æÀ» ¿¾î À¯¹æ¾Ï Áø´Ü ½ÃÀåÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.
¿¬±¸°³¹ß¿¡ ´ëÇÑ ÀÇ·áºñ ÁöÃâ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Roche Diagnostics´Â ÃÖ±Ù °í±Þ ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» Ȱ¿ëÇÏ¿© Ä¡·á ¹æÄ§À» °áÁ¤ÇÏ´Â »õ·Î¿î À¯¹æ¾Ï ºÐ¼®¹ýÀ» ¹ßÇ¥Çߴµ¥, ÀÌ´Â Á¤¹ÐÀÇ·á¿Í ¸ÂÃãÇü ÀǷḦ ÇâÇÑ Àü·«Àû ¿òÁ÷ÀÓÀÔ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå Âü¿©Àڵ鰣ÀÇ Á¦ÈÞ¿Í Çù·Â °ü°è´Â Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ±â¾÷ÀÇ Áö¼ÓÀûÀÎ R&D ÅõÀÚ·Î À¯¹æ¾Ï Áø´Ü ½ÃÀåÀº Å« ÆøÀÇ ¼ºÀåÀÌ ¿¹»óµÇ¸ç, »õ·Î¿î Áø´Ü ¼Ö·ç¼ÇÀ¸·Î Á¶±â ¹ß°ß°ú Ä¡·á ¿É¼ÇÀÌ °ÈµÉ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ±×·¯³ª ÷´Ü Áø´Ü ±â¼ú¿¡ ´ëÇÑ ³ôÀº ºñ¿ë°ú ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼ÀÇ Á¢±Ù¼º Á¦ÇÑÀÌ ½ÃÀå ¼ºÀåÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â Portre's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº À¯¹æ¾Ï Áø´Ü ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯¹æ¾Ï Áø´Ü »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
½ÃÀå ¼¼ºÐÈ
À¯¹æ¾Ï Áø´Ü ½ÃÀå ¼¼ºÐÈ´Â ±¹°¡º°, Áö¿ªº° ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© °¢ Á¦Ç° ¹× ¼ºñ½ºÀÇ Å¸±êÃþÀ» ½Äº°Çϰí ÇâÈÄ ºñÁî´Ï½º ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.
Áö¿ª ºÐ¼®
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.
Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. Value Market ResearchÀÇ Á¶»çÆÀÀÌ °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü ¸®Æ÷Æ®¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå °³¿ä
- ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
- ¼¼°è ½ÃÀå ½º³À¼ô
Á¦3Àå À¯¹æ¾Ï Áø´Ü : »ê¾÷ ºÐ¼®
- ¼·Ð : ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
- ¾÷°è µ¿Çâ
- Porter's Five Forces ºÐ¼®
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®
- ¹ë·ùüÀÎ ºÐ¼®
- ¿øÀç·á ºÐ¼®
- ¿øÀç·á ¸®½ºÆ®
- ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
- ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
- ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
- ¸¶ÄÉÆÃ Ã¤³Î
- ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
- ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
- ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ
Á¦5Àå ¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå ºÐ¼® : À¯Çüº°
- °³¿ä : À¯Çüº°
- ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® : À¯Çüº°
- À̹Ì¡
- »ý°Ë
- °Ô³ð °Ë»ç
- Ç÷¾×°Ë»ç
- ±âŸ
Á¦6Àå ¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå ºÐ¼® : Á¦Ç°º°
- °³¿ä : Á¦Ç°º°
- ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® : Á¦Ç°º°
- Ç÷§Æû ±â¹Ý Á¦Ç°(Â÷¼¼´ë ½ÃÄö½Ì, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, PCR, ±âŸ)
- ±â±â ±â¹Ý Á¦Ç°(À̹Ì¡, »ý°Ë)
Á¦7Àå ¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå ºÐ¼® : ¿ëµµº°
- °³¿ä : ¿ëµµº°
- ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® : ¿ëµµº°
- ½ºÅ©¸®´×
- Áø´Ü¡¤¿¹Ãø
- ¿¹ÈÄ
- ¿¬±¸
Á¦8Àå ¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
- °³¿ä : ÃÖÁ¾ ¿ëµµº°
- ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
- º´¿ø¡¤Áø·á¼Ò
- Áø´Ü ¼¾ÅÍ¡¤ÀÇ·á ¿¬±¸¼Ò
- ±âŸ
Á¦9Àå ¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå ºÐ¼® : Áö¿ªº°
- Áö¿ªº° Àü¸Á
- ¼·Ð
- ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- ºÏ¹Ì : ºÎ¹®º°
- ºÏ¹Ì : ±¹°¡º°
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- À¯·´ : ºÎ¹®º°
- À¯·´ : ±¹°¡º°
- ¿µ±¹
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- È£ÁÖ
- µ¿³²¾Æ½Ã¾Æ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
- ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Æä·ç
- Ä¥·¹
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- À̽º¶ó¿¤
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå À¯¹æ¾Ï Áø´Ü ±â¾÷ÀÇ °æÀï ±¸µµ
- À¯¹æ¾Ï Áø´Ü ½ÃÀåÀÇ °æÀï
- ÆÄÆ®³Ê½Ê/Á¦ÈÞ/ÇÕÀÇ
- ÇÕº´¡¤Àμö
- ½ÅÁ¦Ç°ÀÇ Ãâ½Ã
- ±âŸ °³¹ß
Á¦11Àå ±â¾÷ °³¿ä
- »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
- ½ÃÀå ÁýÁßµµ
- Hologic Inc.
- Genomic Health(Exact Sciences Corporation)
- BD
- Danaher
- Koninklijke Philips N.V.
- QIAGEN
- Thermo Fisher Scientific Inc.
- Myriad Genetics Inc.
- Argon Medical Devices Inc.
- F. Hoffmann-La Roche Ltd
KSA
The global demand for Breast Cancer Diagnostics Market is presumed to reach the market size of nearly USD 10.47 Billion by 2032 from USD 5.22 Billion in 2023 with a CAGR of 8.05% under the study period 2024-2032.
Breast cancer diagnostics involves a range of techniques and tools used to identify and evaluate breast cancer at phases. This area combines imaging methods, like mammography, ultrasound and MRI, biopsy procedures, and molecular testing to achieve accurate diagnosis and staging. These diagnostic methods play a role in detection, which greatly improves the outlook and effectiveness of treatment. Modern diagnostic strategies often merge techniques to improve sensitivity and specificity, allowing healthcare providers to spot tumors at the right stage. Recent advancements in this field include breast tomosynthesis for precise three-dimensional imaging and liquid biopsies that examine circulating tumor DNA for noninvasive cancer detection. This holistic approach ensures personalized treatment plans, ultimately leading to patient outcomes and progress in personalized medicine.
Market Dynamics
The breast cancer diagnostics market is driven by a combination of factors, including increasing incidence of breast cancer, advancements in diagnostic technology, and heightened awareness about early detection. This rising burden underscores the need for enhanced diagnostic tools and services. Technological advancements such as MRI, digital mammography, and innovative biomarkers are transforming diagnostics, improving early detection, and enhancing diagnostic accuracy. For instance, the development of AI in imaging is significantly propelling the precision of breast cancer detection. Key players like Siemens Healthineers & GE Healthcare are incorporating AI algorithms to support radiologists in identifying anomalies with greater accuracy and efficiency. Market opportunities are further propelled by the growing adoption of personalized medicine, which requires advanced diagnostic tools for personalized treatments for individual patients. The implementation of next-generation sequencing technologies and liquid biopsies is creating new avenues for noninvasive monitoring and precise diagnosis, thus expanding the breast cancer diagnostics market.
The escalating healthcare spending in research and development is also fuelling market growth. For instance, Roche Diagnostics has recently introduced a new breast cancer assay that leverages advanced molecular profiling to guide treatment decisions, representing a strategic move towards precision and personalized medicine. In addition, partnerships and collaborations among key market players are driving innovation. As market players continue to spend on cutting-edge research and development, the breast cancer diagnostics market is projected for significant growth, with new diagnostic solutions enhancing early detection and treatment options. However, high costs concerned with advanced diagnostic technologies and limited access in low-resource settings hamper market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Breast Cancer Diagnostics. The growth and trends of Breast Cancer Diagnostics industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Breast Cancer Diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Imaging
- Biopsy
- Genomic Tests
- Blood Tests
- Others
By Product
- Platform-based Products (Next-generation Sequencing, Microarrays, PCR, Others)
- Instrument-based Products (Imaging, Biopsy)
By Application
- Screening
- Diagnostic and Predictive
- Prognostic
- Research
By End-use
- Hospitals & Clinics
- Diagnostic Centers and Medical Laboratories
- Others
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Breast Cancer Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Breast Cancer Diagnostics market include Hologic Inc., Genomic Health (Exact Sciences Corporation), BD, Danaher, Koninklijke Philips N.V., QIAGEN, Thermo Fisher Scientific Inc., Myriad Genetics Inc., Argon Medical Devices Inc., F. Hoffmann-La Roche Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. BREAST CANCER DIAGNOSTICS - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Product
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET ANALYSIS BY TYPE
- 5.1. Overview By Type
- 5.2. Historical and Forecast Data Analysis By Type
- 5.3. Imaging Historic and Forecast Sales By Regions
- 5.4. Biopsy Historic and Forecast Sales By Regions
- 5.5. Genomic Tests Historic and Forecast Sales By Regions
- 5.6. Blood Tests Historic and Forecast Sales By Regions
- 5.7. Others Historic and Forecast Sales By Regions
6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET ANALYSIS BY PRODUCT
- 6.1. Overview By Product
- 6.2. Historical and Forecast Data Analysis By Product
- 6.3. Platform-based Products (Next-generation Sequencing, Microarrays, PCR, Others) Historic and Forecast Sales By Regions
- 6.4. Instrument-based Products (Imaging, Biopsy) Historic and Forecast Sales By Regions
7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET ANALYSIS BY APPLICATION
- 7.1. Overview By Application
- 7.2. Historical and Forecast Data Analysis By Application
- 7.3. Screening Historic and Forecast Sales By Regions
- 7.4. Diagnostic and Predictive Historic and Forecast Sales By Regions
- 7.5. Prognostic Historic and Forecast Sales By Regions
- 7.6. Research Historic and Forecast Sales By Regions
8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET ANALYSIS BY END-USE
- 8.1. Overview By End-use
- 8.2. Historical and Forecast Data Analysis By End-use
- 8.3. Hospitals & Clinics Historic and Forecast Sales By Regions
- 8.4. Diagnostic Centers and Medical Laboratories Historic and Forecast Sales By Regions
- 8.5. Others Historic and Forecast Sales By Regions
9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY
- 9.1. Regional Outlook
- 9.2. Introduction
- 9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
- 9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
- 9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
- 9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
- 9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis
10. COMPETITIVE LANDSCAPE OF THE BREAST CANCER DIAGNOSTICS COMPANIES
- 10.1. Breast Cancer Diagnostics Market Competition
- 10.2. Partnership/Collaboration/Agreement
- 10.3. Merger And Acquisitions
- 10.4. New Product Launch
- 10.5. Other Developments
11. COMPANY PROFILES OF BREAST CANCER DIAGNOSTICS INDUSTRY
- 11.1. Top Companies Market Share Analysis
- 11.2. Market Concentration Rate
- 11.3. Hologic Inc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
- 11.4. Genomic Health (Exact Sciences Corporation)
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
- 11.5. BD
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
- 11.6. Danaher
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
- 11.7. Koninklijke Philips N.V.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
- 11.8. QIAGEN
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
- 11.9. Thermo Fisher Scientific Inc.
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
- 11.10. Myriad Genetics Inc.
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
- 11.11. Argon Medical Devices Inc.
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
- 11.12. F. Hoffmann-La Roche Ltd
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies